Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Paul Nathan, Paolo Ascierto, John Haanen, Enrique Espinosa, Lev Demidov, Claus Garbe, Michele Guida, Paul Lorigan, Vanna Chiarion-Sileni, Helen Gogas, Michele Maio, Maria Fierro, Christoph Hoeller, Patrick Terheyden, Ralf Gutzmer, Tormod Guren, Dimitrios Bafaloukos, Piotr Rutkowski, Ruth Plummer, Ashita Waterston, Martin Kaatz, Mario Mandala, Ivan Marquez-Rodas, Eva Muñoz-Couselo, Reinhard Dummer, Elena Grigoryeva, Tina Young, Dirk Schadendorf (2019) Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) Eur J Cancer (IF: 7.1) 119 168-178Links
http://www.ncbi.nlm.nih.gov/pubmed/31445199http://dx.doi.org/10.1016/j.ejca.2019.07.010
Similar articles
Tools
Download Stork Mobile App
